Oxford, United Kingdom
CEO – Chief Executive Officer
Healthcare & Life Sciences / Biotech
Permanent
£300k – £400k + equity
Role Overview
JOlivier & Partners has been retained by the board of an Oxford-based clinical-stage biotech to identify a new CEO to lead through Phase 3 trials and potential NASDAQ IPO or pharma partnership.
The Organisation & Context
Our client is an Oxford University spin-out developing a first-in-class oncology therapeutic with a Phase 3 trial reading out in 18 months, $120m in funding and a strong IP estate.
Key Responsibilities
- Lead the executive team through Phase 3 completion and regulatory submissions
- Define the business development strategy — partnership vs IPO
- Manage investor relationships and lead the next financing round ($150-200m)
- Build commercial infrastructure for potential product launch
- Represent the company at scientific and regulatory forums
Candidate Profile
- CEO or COO at a clinical-stage biotech or specialty pharma
- Track record of Phase 3 leadership and regulatory approval or major partnership
- Experience with NASDAQ IPO preparation or major pharma licensing
- Deep credibility with scientific leadership and institutional investors
Search Process & Confidentiality
Retained mandate. Equity represents a significant component of total compensation.
JOlivier & Partners
▾
Français 
Español 
Italiano 
Português